Xencor

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

Industries

Stage

Post IPO Equity

Employees

201-500

Links

Org chart

Bassil I. Dahiyat
President, CEO & Director
Collapse
John J. Kuch
SVP & CFO
Allen Yang
SVP & Chief Medical Officer
John R. Desjarlais
SVP, Research & Chief Scientific Officer
Celia Eckert
SVP, General Counsel & Corporate Secretary
Kirk Rosemark
SVP, Regulatory Affairs & Quality Assurance
Eric P. Kowack
VP, Program Leadership & Strategic Alliances
Jeremy Grunstein
VP, Business Development
Jennifer Sandoz
VP, Human Resources